Shanghai Fosun Pharmaceutical Group Co Ltd Capital Reinvestment Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd capital reinvestment ratio. Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Capital Reinvestment Ratio of 0.53x as of December 2025, meaning it reinvests 1% of its operating cash flow (CN¥2.40 Billion) in capital expenditures (CN¥1.28 Billion). See 600196 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Capital reinvestment ratio of Shanghai Fosun Pharmaceutical Group Co Ltd from 1998 to 2025. This chart tracks Shanghai Fosun Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 28 annual periods. See Shanghai Fosun Pharmaceutical Group Co L leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Shanghai Fosun Pharmaceutical Group Co Ltd Capital Reinvestment Ratio by Year (1998–2025)
Shanghai Fosun Pharmaceutical Group Co Ltd capital reinvestment ratio by year from 1998 to 2025. For the full cash flow conversion analysis, see how efficiently does Shanghai Fosun Pharmaceutical Group Co L generate cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.74x | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -24.8% |
| 2024 | 0.99x | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -19.5% |
| 2023 | 1.22x | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -12.4% |
| 2022 | 1.40x | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +10.9% |
| 2021 | 1.26x | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -26.8% |
| 2020 | 1.72x | CN¥2.58 Billion | CN¥4.44 Billion | ▲ +39.9% |
| 2019 | 1.23x | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +14.2% |
| 2018 | 1.08x | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +27.9% |
| 2017 | 0.84x | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -7.6% |
| 2016 | 0.91x | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +19.5% |
| 2015 | 0.76x | CN¥1.62 Billion | CN¥1.24 Billion | ▼ -18.3% |
| 2014 | 0.93x | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥66.55 Million | CN¥52.25 Million | — |